

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse IL-17 RC in direct ELISAs and Western blots. In direct ELISAs, approximately 10% cross-reactivity with recombinant human IL-17 RC is observed and less than 5% cross-reactivity with recombinant mouse (rm) IL-17 RD and rmIL
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse IL-17 RC Leu21-Trp465 Accession # AAH04759
Conjugate	Alexa Fluor 350 Excitation Wavelength: 346 nm Emission Wavelength: 442 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

CyTOF-ready	Optimal dilution of this antibody should be experimentally determined.
Neutralization	Optimal dilution of this antibody should be experimentally determined.
Western Blot	Optimal dilution of this antibody should be experimentally determined.
Flow Cytometry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

IL-17 receptor C (IL-17 RC; also known as IL-17 RL) is an 85-110 kDa member of the IL-17 receptor family. This is one of five families, termed IL-17 RA, B, C, D and E, that comprise the cytokine receptor superfamily (1-6). Not all receptors appear to bind known members of the IL-17 cytokine family. To date, IL-17 RA is reported to bind IL-17A, while IL-17 RB is reported to bind IL-17B and IL-17E (2, 4). Mouse IL-17 RC is a type I transmembrane glycoprotein that is expressed on a variety of nonhematopoietic cell types. Full-length IL-17 RC is synthesized as a 674 amino acid (aa) precursor. It contains a 21 aa signal sequence, a 419 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 213 aa cytoplasmic region. There are multiple potential N-linked glycosylation sites in the ECD and potential phosphorylation sites in the cytoplasmic tail. Four mouse variants have been identified that have been designated mIL-17 RC (7). The isoform expressed here as an R&D product is an unusual 567 aa form (8). Its precursor contains a 20 aa signal sequence, a 444 aa extracellular region, a 20 aa transmembrane segment and an 83 aa cytoplasmic tail. When compared to the full length mouse IL-17 RC form, this expressed isoform's extracellular region shows absolute aa identity, save for an additional 24 aa insert. In the cytoplasmic region, it is highly divergent and shows virtually no aa identity (8-9). The extracellular region of mouse IL-17 RC shows about 70% aa identity to the equivalent region in human IL-17 RC isoform # 3. IL-17 RC is the cognate receptor for IL-17F (7). In humans, IL-17 RC binds IL-17A with similar affinity, and with IL-17 RA, it forms a definitive receptor for both IL-17A and IL-17F (7). The stoichiometry is unclear; it may form a heterodimer with IL-17 RA, or a heterotrimer with a preexisting IL-17 RA homodimer (4, 7, 10, 11). The heteromeric nature of the receptor may be important given that the predominant form of the IL-17 cytokine is now considered to be an IL-17A:IL-17F heterodimer (4).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.